TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...
Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback